Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verona Pharma (VRNA)
:VRNA
Holding VRNA?
Track your performance easily
VRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.39 - $55.42
Previous CloseN/A
Volume658.49K
Average Volume (3M)1.20M
Market Cap
$4.39B
Enterprise Value$2.23B
Total Cash (Recent Filing)$39.78M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Feb 27, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding81,831,170
10 Day Avg. Volume1,906,388
30 Day Avg. Volume1,204,763
Standard Deviation0.24
R-Squared0.00741
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)732.03
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue397.02
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.23
Forecast
1Y Price Target
$58.86Price Target Upside9.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Verona Pharma News
Bulls Say, Bears Say
Bulls Say
Market OpportunityEarly feedback suggests Ohtuvayre could be a ~$2B drug, with $3B+ being a real possibility.
Regulatory ApprovalOhtuvayre received FDA approval for COPD and became commercially available, contributing to sales growth.
Sales PerformanceOhtuvayre's initial sales beat expectations, leading to an increase in the price target.
Bears Say
Commercial UptakeSlower-than-anticipated commercial uptake of ensifentrine in the U.S. due to greater-than-projected competitive pressures or other market challenges.
CompetitionCompetition in a market dominated by large pharma poses significant challenges.
Trial DesignRisks associated with trial design may impact the stock's performance.
---
Ownership Overview
42.79% Insiders
12.62% Mutual Funds
0.25% Other Institutional Investors
43.68% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRNA FAQ
What was Verona Pharma’s price range in the past 12 months?
Verona Pharma lowest stock price was $11.39 and its highest was $55.42 in the past 12 months.
What is Verona Pharma’s market cap?
Verona Pharma’s market cap is $4.39B.
When is Verona Pharma’s upcoming earnings report date?
Verona Pharma’s upcoming earnings report date is Feb 27, 2025 which is in 40 days.
How were Verona Pharma’s earnings last quarter?
Verona Pharma released its earnings results on Nov 04, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.002.
Is Verona Pharma overvalued?
According to Wall Street analysts Verona Pharma’s price is currently Undervalued.
Does Verona Pharma pay dividends?
Verona Pharma does not currently pay dividends.
What is Verona Pharma’s EPS estimate?
Verona Pharma’s EPS estimate is -0.07.
How many shares outstanding does Verona Pharma have?
Verona Pharma has 81,831,170 shares outstanding.
What happened to Verona Pharma’s price movement after its last earnings report?
Verona Pharma reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went up 9.062%.
Which hedge fund is a major shareholder of Verona Pharma?
Currently, no hedge funds are holding shares in VRNA
---
Verona Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.86 (9.73% Upside)
$58.86 (9.73% Upside)
Blogger Sentiment
Neutral
VRNA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $475.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.92%
12-Months-Change
Fundamentals
Return on Equity
-78.35%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Verona Pharma
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
---
VRNA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive sentiment primarily due to the successful launch of Ohtuvayre, robust prescriber engagement, and the initiation of new clinical trials. Despite the increased expenses and significant net loss, the overall outlook remains positive with promising early sales and a solid financial position.Read More>---
VRNA Stock 12 Month Forecast
Average Price Target
$58.86
▲(9.73% Upside)
Technical Analysis
ESSA Pharma
―
Aclaris Therapeutics
―
Blueprint Medicines
―
Rigel
―
Kiniksa Pharmaceuticals
―
TG Therapeutics
―
Best Analysts Covering VRNA
1 Year
1 Year Success Rate
17/20 ratings generated profit
1 Year Average Return
+116.75%
reiterated a buy rating 11 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +116.75% per trade.
---